Bolt Biotherapeutics, Inc. (BOLT)
| Market Cap | 8.82M -36.3% |
| Revenue (ttm) | 7.70M +0.1% |
| Net Income | -33.38M |
| EPS | -17.85 |
| Shares Out | 1.92M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 24,595 |
| Open | 4.600 |
| Previous Close | 4.590 |
| Day's Range | 4.500 - 4.790 |
| 52-Week Range | 3.910 - 9.248 |
| Beta | 1.10 |
| Analysts | Strong Buy |
| Price Target | 34.00 (+640.74%) |
| Earnings Date | May 13, 2026 |
About BOLT
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company’s pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembr... [Read more]
Financial Performance
In 2025, Bolt Biotherapeutics's revenue was $7.70 million, an increase of 0.07% compared to the previous year's $7.69 million. Losses were -$33.38 million, -47.12% less than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for BOLT stock is "Strong Buy." The 12-month stock price target is $34.0, which is an increase of 640.74% from the latest price.
News
Bolt Biotherapeutics reports Q4 EPS ($3.84), consensus ($5.52)
Reports Q4 revenue $2.5M, consensus $857,250. “BDC-4182 is the first of our next-generation Boltbody ISACs to enter the clinic, and we saw a clear difference versus our first-gen ISACs in
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
REDWOOD CITY, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, t...
Bolt Biotherapeutics to Participate in Upcoming March Conferences
REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, to...
Bolt Biotherapeutics reports Q3 EPS ($3.72), consensus ($5.39)
Reports Q3 revenue $2.17M, consensus $820,800. “In the third quarter, we focused on developing BDC-4182, the first next-generation Boltbody ISAC in our pipeline. We are actively enrolling patients wit...
Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Initial clinical data for BDC-4182 Phase 1 dose escalation study expected in 3Q 2026 Cash balance of $38.8 million as of September 30, 2025 anticipated to fund key milestones into 2027 REDWOOD CITY, ...
Bolt Biotherapeutics assumed with a Buy at H.C. Wainwright
H.C. Wainwright assumed coverage of Bolt Biotherapeutics (BOLT) with a Buy rating and $7 price target The company’s lead asset, BDC-4182, differentiates itself relative to antibody-drug conjugates sin...
Bolt Biotherapeutics to reduce workforce by 50%, gives update on BDC-4182 study
Bolt Biotherapeutics (BOLT) announced an update on the ongoing Phase 1 dose escalation study of BDC-4182, a Boltbody ISAC clinical candidate targeting claudin 18.2, a clinically validated target in on...
Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027
REDWOOD CITY, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, to...
Bolt Biotherapeutics target adjusted to $75 at Lake Street after reverse split
Lake Street analyst Chad Messer raised the firm’s price target on Bolt Biotherapeutics (BOLT) to $75 from $4 and keeps a Buy rating on the shares after Bolt ended Q2
Bolt Biotherapeutics reports Q2 EPS ($4.46), consensus ($6.27)
Reports Q2 revenue $1.8M, consensus $819,750. “In the second quarter we focused on advancing BDC-4182, the first next-generation Boltbody(TM) ISAC in our pipeline,” said Willie Quinn, president and CE...
Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
REDWOOD CITY, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, to...
Bolt Biotherapeutics Inc trading halted, news pending
19:50 EDT Bolt Biotherapeutics (BOLT) Inc trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-...
Bolt Biotherapeutics initiated with a Buy at Lake Street
Lake Street initiated coverage of Bolt Biotherapeutics (BOLT) with a Buy rating and $4 price target. Bolt has developed next-generation Immune-Stimulating Antibody Conjugates, or ISACs, with optimized...
Bolt Biotherapeutics price target lowered to $1 from $1.25 at Stifel
Stifel analyst Stephen Willey lowered the firm’s price target on Bolt Biotherapeutics (BOLT) to $1 from $1.25 and keeps a Hold rating on the shares following management’s earnings announcement, corpor...
Bolt Biotherapeutics Transcript: Status Update
BDC-3042 demonstrated strong safety and early efficacy in phase I, especially in refractory NSCLC, with a confirmed partial response and ongoing stable disease. BDC-4182's trial is open, targeting a broader Claudin 18.2 market, and partnering discussions for BDC-3042 are progressing.
Bolt Biotherapeutics reports Q1 EPS (29c), consensus (36c)
Reports Q1 revenue $1.22M, consensus $768K. Reports cash balance of $58.0M as of March 31, which is anticipated to fund key milestones through mid-2026. Published first on TheFly – the
Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
REDWOOD CITY, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, tod...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Sarepta (SRPT), 866% surge in interest Bolt Biotherapeuti...
Bolt Biotherapeutics to host KOL call on BDC-3042 Phase 1 results
Bolt Biotherapeutics (BOLT) will host a key opinion leader conference call and webcast featuring Ecaterina Dumbrava, M.D., associate professor of Investigational Cancer Therapeutics at The University ...
Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates
Conference call and webcast on Monday, May 12, 2025, at 2:30 p.m. PT / 5:30 p.m.
Bolt Biotherapeutics announces results for Boltbody ISACs at AACR meeting
Bolt Biotherapeutics (BOLT) announced preclinical results from its next-generation Boltbody ISACs targeting CEACAM5 and PD-L1 at the American Association for Cancer Research annual meeting. Key result...
Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025
CEA-targeted ISAC elicits complete responses in mice and is well-tolerated in NHPs PD-L1 ISAC directly activates and reprograms PD-L1-expressing myeloid cells in the TME to drive complete responses an...
Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025
BDC-3042 was well tolerated up to 10 mg/kg q2w with no dose-limiting toxicities and no drug-related serious adverse events
Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025
REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, t...
Bolt Biotherapeutics reports Q4 EPS (42c), consensus (35c)
Bolt Biotherapeutics (BOLT) reported financial results for the third quarter ended December 31 and provided a business update. “2024 was a transformational year for Bolt as we focused the company